Phesgo pdf
WebThe most common adverse reactions (>30%) with PHESGO were alopecia, nausea, diarrhea, anemia, and asthenia. Metastatic Breast Cancer (based on IV pertuzumab) The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral … WebJan 1, 2024 · for PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Breast Cancer The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for PHESGO effective January 1, 2024. TYPE CODE DESCRIPTION Diagnosis: ICD-10-CM C50.011–C50.019 C50.111–C50.119 C50.211–C50.219 C50.311–C50.319 …
Phesgo pdf
Did you know?
WebNov 1, 2024 · Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection is a sterile, preservative-free, clear to opalescent, and colorless to slightly brownish solution … WebMar 1, 2024 · • PHESGO recognizes the cancer cells in the body called “human epidermal growth factor 2” or HER2 for short. HER2 is found in large amounts on the surface of …
WebPhesgo pertuzumab, trastuzumab, and hyaluronidase-zzxf Dose: Frequency: F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable. Primary ICD Code: Secondary ICD Code: Other ICD Code: G. CLINICAL INFORMATION WebIndications & Important Safety Information Early Breast Cancer PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for • t he neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer
WebMay 2, 2024 · Phesgo (1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase per 15 mL) single-dose vial: 50242-0245-xx Phesgo (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase per 10 mL) single-dose vial: 50242-0260-xx VII. References (STANDARD) 1. Phesgo [package insert]. WebPHESGO™ (pertuzumab, trastuzumab and hyaluronidase-zzxf) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2024, …
WebPHESGO is a fixed-dose subcutaneous formulation with PERJETA®(pertuzumab) and trastuzumab that’s administered in ~5 minutes*1 *Refers to actual PHESGO injection time …
Web4. Will Phesgo be used intravenously? Yes No 5. Will Phesgo be administered by a healthcare professional? Yes No 6. FEMALE Patient: Is the patient of child-bearing potential? Yes* No *If YES, will the patient be advised to use effective contraception during treatment with Phesgo and for seven months after the last dose? Yes No dr curtis manningWebPhesgo (pertuzumab / trastuzumab / hyaluronidase) PHYSICIAN INFORMATION PATIENT INFORMATION * Physician Name: *Due to privacy regulations we will not be able to … dr curtis lubbockWebPhesgo 600-600mg-20,000units vial Phesgo 1,200-600mg-30,000units vial Directions for use: Dose: Quantity: Duration of therapy: Where will this medication be obtained? Accredo Specialty Pharmacy** Prescriber’s office stock (billing on a medical claim form) Other (please specify): ... dr curtis mann northshoreWebWhat does PHESGO treat? PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: • use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, infl ammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter energy lunch mealsWebPatient Quick Hit - phesgo energy lost in collisionWebThe use of pertuzumab, trastuzumab, and hyaluronidase (Phesgo) may be considered medically necessary in individuals 18 years of age and older for the following: • As therapy in combination with chemotherapy for: EITHER. of the following: o Neoadjuvant treatment of individuals with HER2-positive, locally advanced, dr curtis marr portlandWebwww.linkos.cz energy management by murphy